BIO Proposes Increased Imputed Base Rates for 2002 Medicare OPPS
This article was originally published in The Gray Sheet
The Biotechnology Industry Organization (BIO) says it will seek a blended reimbursement rate of 80% of the average wholesale price (AWP) for drugs and biologics if the trade group is unable to delay the Centers for Medicare & Medicaid Services' 68.9% pro rata reduction in "pass-through" payments for new medical technologies
You may also be interested in...
The Medicare Payment Advisory Commission's upcoming recommendation on the future of the hospital outpatient prospective payment system (OPPS) "pass-through" payments is likely to hinge on the panel's perception of the size of the administrative undertaking for the Center for Medicare & Medicaid Services in implementing the system
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.